<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104985</url>
  </required_header>
  <id_info>
    <org_study_id>LLLT-trophic-ulcers-Tula</org_study_id>
    <nct_id>NCT03104985</nct_id>
  </id_info>
  <brief_title>LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency</brief_title>
  <official_title>New Combined Laser Therapy in Patients With Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Center Matrix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Center Matrix</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate comparatively the efficiency of traditional treatment
      methods in patients with chronic venous diseases of C6 class, and a new combined low level
      laser therapy (LLLT) by LASMIK device.

      The results of outpatient examination and treatment of patients with venous trophic ulcers,
      observed in the City Polyclinic of &quot;Tula Municipal Clinical Hospital №2&quot; were analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During a longitudinal study, a group of patients was followed up in the period of complete or
      partial recovery. International classification of lower extremity chronic venous disorders
      СЕАР was used as a clinical classification of chronic venous insufficiency (CVI).

      Depending on the applied treatment method, patients were divided into 2 groups:

        1. (n=34) Conventional treatment

        2. (n=34) Conventional treatment + combined LLLT, including external exposure with 635nm
           wavelength + intravenous laser blood illumination (ILBI) with 365-405nm (UV-spectrum)
           and 520-525nm (green spectrum) wavelength alternately, according to the special scheme
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Trophic Ulcer Healing</measure>
    <time_frame>6 months follow up</time_frame>
    <description>Number of participants with ulcer epithelialization was counted in both groups. Trophic ulcer healing in 6 months occurred in larger number of participants of conventional therapy and combined LLLT group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Trophic Ulcers</condition>
  <condition>Chronic Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment only.
An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2
Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.
Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional therapy and combined LLLT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:
- 365-405nm, power 1-2mW, exposure 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LASMIK</intervention_name>
    <description>the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).</description>
    <arm_group_label>Conventional therapy and combined LLLT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>An elastic compression of lower extremities,
Pharmacotherapy,
Topical treatment</description>
    <arm_group_label>Conventional therapy and combined LLLT</arm_group_label>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18 years of age,

          -  CVI Stage 6 (S6) in compliance with СЕАР

        Exclusion Criteria:

          -  hemorrhagic syndrome,

          -  neoplastic syndrome,

          -  hyperthermic syndrome (fever, patient body temperature over 38°C),

          -  syndrome of systemic (cardiac, vascular, respiratory, renal and hepatic) and multiple
             organ failure (general severe illness),

          -  cachexic syndrome (severe general exhaustion),

          -  epileptic syndrome,

          -  hysterical syndrome,

          -  convulsive syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Moskvin</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Scientific Center of Laser Medicine, Russia, Moscow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tula Municipal Clinical Hospital №2</name>
      <address>
        <city>Tula</city>
        <zip>300002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.lazmik.ru</url>
    <description>Educational website with publications, scientific articles, training manuals, guidelines, books on LLLT.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>February 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trophic ulcer; low level laser therapy; Chronic Venous Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conventional Treatment</title>
          <description>An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2
Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.
Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin).
Conventional therapy: - An elastic compression of lower extremities,
Pharmacotherapy,
Topical treatment</description>
        </group>
        <group group_id="P2">
          <title>Conventional Therapy and Combined LLLT</title>
          <description>External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:
- 365-405nm, power 1-2mW, exposure 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min;
- 365-405nm, 1-2mW, 2 min;
- 520-525nm, 1-2mW, 5 min</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional Treatment</title>
          <description>Conventional treatment only.</description>
        </group>
        <group group_id="B2">
          <title>Conventional Therapy and Combined LLLT</title>
          <description>Conventional therapy and combined LLLT (LASMIK device)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" lower_limit="39" upper_limit="77"/>
                    <measurement group_id="B2" value="57.5" lower_limit="40" upper_limit="78"/>
                    <measurement group_id="B3" value="57.2" lower_limit="39" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="34"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Trophic Ulcer Healing</title>
        <description>Number of participants with ulcer epithelialization was counted in both groups. Trophic ulcer healing in 6 months occurred in larger number of participants of conventional therapy and combined LLLT group.</description>
        <time_frame>6 months follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Treatment</title>
            <description>Conventional treatment only.</description>
          </group>
          <group group_id="O2">
            <title>Conventional Therapy and Combined LLLT</title>
            <description>Conventional therapy and combined LLLT (LASMIK device).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Trophic Ulcer Healing</title>
          <description>Number of participants with ulcer epithelialization was counted in both groups. Trophic ulcer healing in 6 months occurred in larger number of participants of conventional therapy and combined LLLT group.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conventional Treatment</title>
          <description>Conventional treatment only.</description>
        </group>
        <group group_id="E2">
          <title>Conventional Therapy and Combined LLLT</title>
          <description>Conventional therapy and combined LLLT (LASMIK device).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sergey Moskvin</name_or_title>
      <organization>State Scientific Center of Laser Medicine, Russia, Moscow</organization>
      <phone>+7-905-770-1860</phone>
      <email>7652612@mail.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

